LLY · Eli Lilly and Company
Is LLY setting up for a breakout, what are traders on X and the news saying, are its insiders buying, and how is the business doing? Everything Raspberry Trades measures on Eli Lilly and Company, in one place.
Today's breakout radarIs LLY setting up for a breakout?
Breakout Radar API →Not today. LLY is not on today's radar: no tight base just under a resistance that has been tested again and again.
See the stocks that are setting up today →What are traders on X saying about LLY?
Stock Sentiment API →Bulls: Lilly won a court ruling against Novo Nordisk, with the judge denying Novo's motion for a preliminary injunction in the GLP-1 false-advertising case and finding a key Novo witness not credible and Novo's own advertising tainted by unclean hands. The pipeline remains the core catalyst: Retatrutide (a GLP-1/GIP/Glucagon triple agonist) is framed as potentially the biggest-grossing pharma product since the Covid jab, a triple-agonist oral peptide is entering Phase 2, and trademark filings point to Retkouro/Retzoundi as likely branded names. One X-PULSE report rates LLY bullish citing 47.7% revenue growth and ~27x forward multiple, while a sentiment tally shows 19 bullish vs 3 bearish sources and +8.1% over 30 days; Ken Langone called LLY potentially the biggest company in the world, and an Elliott Wave setup targets $1,357.70 above the Nov. 2025 low.
Bears: Tolerability data on UBT251 showed only 1 of 155 patients (0.6%) discontinued due to adverse events over 24 weeks, versus 6–16% discontinuations for Retatrutide over 48 weeks — though the items note these are different trials and durations, not a head-to-head comparison. More U.S. employers are dropping GLP-1 weight-loss coverage from Novo and Lilly as healthcare costs rise, per CNBC, and skeptics warn that analyst hype around Retatrutide could backfire on shareholders since it is not FDA-approved and side effects remain a concern.
Reading from Oct 28, 2026; each post classified by AI, weighted by engagement.
What is the news saying about LLY?
News Sentiment API →No recent news reading for LLY. The News Sentiment API reads today's headlines on any US stock.
Are LLY insiders buying or selling?
Insider Trading API →Open-market trades only, from SEC Form 4 filings — option exercises, tax withholding and grants are left out.
- Sold · Jonsson Patrik$7.6M · Aug 17, 2026
- Sold · Zakrowski Donald A$2.4M · Aug 10, 2026
- Sold · Hakim Anat$6.0M · Aug 7, 2026
- Sold · Yuffa Ilya$2.9M · Jun 10, 2026
- Sold · LILLY ENDOWMENT INC$2.2M · May 6, 2026
How is Eli Lilly and Company's business doing?
Financial Statements API →| Quarter ended | Revenue | vs year before | Net income | EPS |
|---|---|---|---|---|
| Jun 30, 2026 | $23.0B | +48% | $7.1B | $7.94 |
| Mar 31, 2026 | $19.8B | +56% | $7.4B | $8.26 |
| Sep 30, 2025 | $17.6B | +54% | $5.6B | $6.21 |
| Jun 30, 2025 | $15.6B | +38% | $5.7B | $6.29 |
From the company's SEC filings (10-Q and 10-K).
What does Eli Lilly and Company expect?
Company Guidance API →- full-year 2026 · revenue · 8-K filed Aug 5, 2026
“Increased 2026 full-year revenue guidance to be in the range of $85.0 billion to $87.0 billion”
- full-year 2026 · revenue · 8-K filed Aug 5, 2026
“Revenue $82 to $85 billion $85 to $87 billion”
- full-year 2026 · performance margin · 8-K filed Aug 5, 2026
“Performance Margin (1)(2) 47.0% to 48.5% 49.0% to 50.5%”
- full-year 2026 · revenue · 8-K filed Feb 4, 2026
“Revenue $80 to $83 billion”
Quoted from the outlook the company filed with the SEC.
Free account, no card: today's top 5 with charts, by email before the open.
Measured data, not recommendations. Not investment advice.